

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF                      ART UNIT: 1614  
HOLMES, DAVID GRENVILLE ET AL.                                      EXAMINER: ROYDS, LESLIE A  
INTERNATIONAL APPLICATION NO: PCT/EP03/05762  
FILED: JUNE 02, 2003  
U.S. APPLICATION NO: 10/516633  
35 USC §371 DATE: JANUARY 19, 2005  
FOR: USE OF SUBSTITUTED CYANOPYRROLIDINES AND  
COMBINATION PREPARATIONS CONTAINING THEM FOR  
TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed April 22, 2009.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

☒ Certificate under 37 C.F.R. §1.97(e)(1): I, the undersigned Attorney, hereby certify that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Respectfully submitted,



Cozette M. McAvoy  
Attorney for Applicant  
Reg. No. 60,457

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9273

Date: *3rd August 2010*